Smith & Nephew (SNN) Stock News

Smith+Nephew (NYSE:SNN) has appointed Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective June 23, 2025. Dhankhar brings 25 years of experience from McKinsey & Company, where he served as Senior Partner and held key positions including Global Head of Strategy and M&A for Life Sciences. He later worked at Lazard Ltd as Managing Director and Global Head of Medical Technology, Diagnostics and Tools. Most recently, he founded Bluish Capital, focusing on growth capital deployment for FDA-approved assets. Dhankhar holds bachelor's degrees in Physics and Computer Science, along with a master's and doctorate in Molecular Biophysics and Biochemistry from Yale University. He will report to CEO Deepak Nath and join the Executive Committee.

Smith+Nephew (NYSE:SNN) has partnered with Standard Health to establish the UK's first Orthopaedic Ambulatory Surgery Centre in Poole, Dorset. The facility will provide both NHS and private patients with access to advanced joint repair and replacement procedures. Standard Health plans to expand to 10 additional UK sites within three years and reach 20 locations by 2030. The center will follow the successful US ASC model, where such facilities show 92% patient satisfaction rates and 40% cost reduction compared to hospital-based surgeries. Set to open in 2025, the Poole facility will serve thousands of patients annually, primarily NHS referrals, helping address the current backlog of over 850,000 people awaiting orthopaedic surgery in the UK. Smith+Nephew will supply its medical technology portfolio while Standard Health manages site development and operations.

Smith+Nephew (NYSE:SNN) has introduced a new medial stabilized insert for its LEGION Total Knee System. The innovation comes as medial stabilized inserts have seen significant growth, increasing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023. The new design features a larger anterior medial lip and medial pivot kinematics to maintain stability, similar to natural knee movement. The system can be used with or without the Posterior Cruciate Ligament, offering greater procedural efficiency and potentially reducing operating time. The LEGION TKS has over 20 years of clinical success, and this new insert supports both LEGION CONCELOC Cementless and LEGION Cemented Total Knee Systems. The product is currently available in the US on a limited basis, with full commercial release planned for later in 2025 and Canadian introduction in 2026.

Smith+Nephew (NYSE:SNN) has secured a significant $75 million contract with the U.S. Department of Defense to provide RENASYS TOUCH Negative Pressure Wound Therapy Systems. The 10-year contract (5 years plus 5 one-year options) was awarded through the Defense Logistics Agency. The RENASYS TOUCH NPWT System, manufactured in the United States, was selected for its clinical efficacy, portability, and intuitive interface. The system will support military medical providers across various care settings, from casualty care to military treatment facilities. This contract builds upon Smith+Nephew's 2024 Master Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research, continuing the company's century-long tradition of supporting military medical needs.

Smith+Nephew (NYSE:SNN) has released findings from a large comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in C-section recovery. The study, analyzing over 10,000 C-section patients, demonstrates that PICO sNPWT significantly reduces surgical site complications and delivers substantial cost savings of $728,220 per 1,000 patients compared to other sNPWT devices. The research shows significant reductions in surgical site infections (SSIs), wound dehiscence, and seroma formation. A complementary survey revealed that mothers with complications were 5 times more likely to describe their recovery as traumatic, with 55% reporting depression. The study is particularly relevant as C-sections account for 32% of US births, with 44.6% considered high-risk, and SSIs alone cost over $900 million annually.

Smith+Nephew (NYSE:SNN) announced impressive results from a multicenter randomized controlled trial for its CARTIHEAL AGILI-C Cartilage Repair Implant. The FDA-approved implant demonstrated 87% lower relative risk of requiring total knee arthroplasty or osteotomy compared to standard care over 4 years. Key findings include:

The implant showed superior pain relief and quality of life improvements over 4 years, with better functional gains in daily activities and sports at 2 and 4 years. Notably, the scaffold effectively treated diverse patient groups regardless of age, lesion size, or osteoarthritis presence.

The technology's broad indication allows treatment of patients who previously had limited options, with comparable results across genders. The findings will be presented at the Arthroscopy Association of North America Annual Meeting (AANA 2025) in Washington DC, May 8-10.

Smith+Nephew (NYSE:SNN) announces its showcase of advanced Orthopaedic Reconstruction technologies at the AAOS 2025 Annual Meeting in San Diego. The company highlights several key innovations:

The CORIOGRAPH Pre-Op Planning and Modeling Services now includes support for hip procedures, featuring simulation of patient-specific daily activities. The CORI Digital Tensioner enhances knee procedure personalization through objective gap data measurements.

The new CATALYSTEM Primary Hip System is designed for modern primary hip surgery, particularly anterior approach procedures. The company's OXINIUM on highly cross-linked polyethylene demonstrates >94.1% survivorship over 20 years in total hip arthroplasty.

Additionally, SNN introduces OXINIUM technology on the LEGION Hinged Knee System and receives FDA 510(k) clearance for the AETOS Stemless anatomic total shoulder system, designed for efficient procedures with maximized metaphyseal fixation.

Smith+Nephew (NYSE:SNN) announces its showcase of advanced Sports Medicine technologies for joint repair at the AAOS 2025 Annual Meeting in San Diego. The company highlights three breakthrough technologies:

1. The TESSA Spatial Surgery System (510(k)-pending) - A revolutionary technology combining personalized operative planning with real-time tracking and augmented reality guidance.

2. The CARTIHEAL AGILI-C Cartilage Repair Implant - An FDA-approved device showing clinical superiority with better knee function, pain relief, and mobility improvements over 4 years, plus lower risk of additional knee surgery.

3. The REGENETEN Bioinductive Implant - A collagen scaffold showing 3x reduction in re-tear risk versus standard repair alone, used in over 150,000 patients with a 15-minute procedure time.

Smith+Nephew (NYSE:SNN) announces exceptional performance of their proprietary OXINIUM™ Technology in total hip arthroplasty, as confirmed by the Australian Orthopaedic Association National Joint Replacement Registry's latest annual report. The data shows OXINIUM on highly cross-linked polyethylene achieved the highest survivorship rate of 94.1% over 20 years among all bearing combinations.

Four global registries, including those from Australia, UK, Italy, and Netherlands, demonstrate that OXINIUM/XLPE had a 35% lower risk of revision at 10-years compared to other modular acetabular implants. The technology features unique benefits including metal durability, ceramic wear resistance, and superior corrosion resistance, with virtually no nickel, cobalt, or chromium content.